R WE ready for reimbursement? A round up of developments in RWE relating to health technology assessment: part 2

Simpson, Alex; Ramagopalan, Sreeram V

doi:10.2217/cer-2021-0144

Cited by 3 publications

(3 citation statements)

References 13 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Related to socioeconomic inequalities, there is also health inequity. There has been a growing interest in considering health inequity in the assessment and reimbursement of new technologies 46 47. The estimated prevalence findings in this study could provide insights to assess potential impacts on equity of novel interventions in AD.…”

Section: Discussionmentioning

confidence: 90%

Estimating the prevalence of diagnosed Alzheimer disease in England across deprivation groups using electronic health records: a clinical practice research datalink study

Leahy,

Simpson,

Sammon

et al. 2023

BMJ Open

Self Cite

View full text Add to dashboard Cite

ObjectiveEstimate the prevalence of diagnosed Alzheimer’s disease (AD) and early Alzheimer’s disease (eAD) overall and stratified by age, sex and deprivation and combinations thereof in England on 1 January 2020.DesignCross-sectional.SettingPrimary care electronic health record data, the Clinical Practice Research database linked with secondary care data, Hospital Episode Statistics (HES) and patient-level deprivation data, Index of Multiple Deprivation (IMD).Outcome measuresThe prevalence per 100 000 of the population and corresponding 95% CIs for both diagnosed AD and eAD overall and stratified by covariates. Sensitivity analyses were conducted to assess the sensitivity of the population definition and look-back period.ResultsThere were 448 797 patients identified in the Clinical Practice Research Datalink that satisfied the study inclusion criteria and were eligible for HES and IMD linkage. For the main analysis of AD and eAD, 379 763 patients are eligible for inclusion in the denominator. This resulted in an estimated prevalence of diagnosed AD of 378.39 (95% CI, 359.36 to 398.44) per 100 000 and eAD of 292.81 (95% CI, 276.12 to 310.52) per 100 000. Prevalence estimates across main and sensitivity analyses for the entire AD study population were found to vary widely with estimates ranging from 137.48 (95% CI, 127.05 to 148.76) to 796.55 (95% CI, 768.77 to 825.33). There was significant variation in prevalence of diagnosed eAD when assessing the sensitivity with the look-back periods, as low as 120.54 (95% CI, 110.80 to 131.14) per 100 000, and as high as 519.01 (95% CI, 496.64 to 542.37) per 100 000.ConclusionsThe study found relatively consistent patterns of prevalence across both AD and eAD populations. Generally, the prevalence of diagnosed AD increased with age and increased with deprivation for each age category. Women had a higher prevalence than men. More granular levels of stratification reduced patient numbers and increased the uncertainty of point prevalence estimates. Despite this, the study found a relationship between deprivation and prevalence of AD.

show abstract

Section: Discussionmentioning

confidence: 90%

Estimating the prevalence of diagnosed Alzheimer disease in England across deprivation groups using electronic health records: a clinical practice research datalink study

Leahy,

Simpson,

Sammon

et al. 2023

BMJ Open

Self Cite

View full text Add to dashboard Cite

show abstract

“…В то время как результатом пандемии стало огромное количество информации, в настоящее время доступ к ней остаётся только для тех, кто исследует COVID-19 и связанные с ним последствия для здоровья, что подчёркивает необходимость в создании подобных интернациональных баз данных и по другим нозологиям. Разумеется, развитие этих инициатив в области данных потребует значительных инвестиций и определения приоритетности ресурсов в долгосрочной перспективе, но уже не является непреодолимой преградой [12].…”

Section: влияние пандемии Covid-19 на Rwd / Rweunclassified

“…Это исследование объединило данные из Бельгийского регистра рака о выживаемости, использовании ЛП с данными о расходах на случаи нетрудоспособности из двух других бельгийских источников RWD. Исследователи изучили взаимосвязь между улучшением выживаемости по 12 [15].…”

Section: ценность инновационных методов для отзunclassified

Role of RWD / RWE in health technology assessment

Borovskaya

Kurylev

2023

MyRWD

View full text Add to dashboard Cite

For many reasons randomized clinical trials today can»t cope with the tasks set by modern health care, which was clearly demonstrated by the COVID-19 pandemic. This gave new impetus to the development of the RWD / RWE. It became obviously that in cases of impossibility, unethical and other reasons, new methods for obtaining high-quality evidence may be effectively used, and later can be used by decision-makers and organizations engaged in the assessment of health technologies.

show abstract

Celebrating 10 years of the Journal of Comparative Effectiveness Research

Dormer

2022

J. Comp. Eff. Res.

View full text Add to dashboard Cite

R WE ready for reimbursement? A round up of developments in RWE relating to health technology assessment: part 2

Abstract: In this round up, we cover how COVID-19 has been beneficial for improved access to real-world data, as well as how real-world data can be used to address health inequity, an area of increasing interest for health technology assessment.

Cited by 3 publications

References 13 publications

Estimating the prevalence of diagnosed Alzheimer disease in England across deprivation groups using electronic health records: a clinical practice research datalink study

Estimating the prevalence of diagnosed Alzheimer disease in England across deprivation groups using electronic health records: a clinical practice research datalink study

Role of RWD / RWE in health technology assessment

Celebrating 10 years of the Journal of Comparative Effectiveness Research

Contact Info

Product

Resources

About